EUVIMEDEUVIMED entdecken
Open Access

Changes in hematological indices during adalimumab therapy in ankylosing spondylitis: a one-year retrospective study

Dominika Szlichta iD, Magdalena Dryglewska iD, Ewa Łyś-Toporowska iD, Maria Majdan iD

Rheumatology · 14.07.2026 · 64 (3) · 174-180

DOI: 10.5114/reum/214444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology, online erschienen am 14.07.2026. Verfasst von Dominika Szlichta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Systemic Connective Tissue Diseases, Medical University of Lublin, Poland. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ankylosing spondylitis (AS) is a chronic inflammatory disease that can be managed with tumor necrosis factor (TNF) inhibitors. This study evaluated the effects of adalimumab, a TNF inhibitor, on inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Monitoring disease activity during therapy is important for assessing treatment response. Material and methods We analyzed the medical history of 28 patients with confirmed AS, treated with adalimumab. The inflammatory markers neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), monocyte–lymphocyte ratio (MLR), CRP, ESR, and the Bath Ankylosing Spondylitis Disease Activity Index were assessed at the beginning of the observation (month 0) and after 3, 6, and 12 months of therapy.

Results

The mean NLR value after 3 months of treatment was 1.48 (95% confidence interval, CI: 0.92–2.03, p < 0.001), after 6 months was 1.48 (95% CI: 0.92–2.12, p < 0.001), and after 12 months was 1.67 (95% CI: 1.08–2.30, p < 0.001). Mean MLR value after 3 months of treatment was 0.07 (95% CI: 0.03–0.13, p = 0.005), after 6 months was 0.05 (95% CI: 0.00–0.11, p = 0.101), and after 12 months was 0.06 (95% CI: 0.01–0.11, p = 0.047), showing statistical significance only after 3 and 12 months. The mean PLR value after 3 months of treatment was 52.8 (95% CI: 30.1–79.60, p < 0.001), after 6 months was 65.50 (95% CI: 31.60–83.90, p < 0.001), and after 12 months was 68.80 (95% CI: 42.70–93.70, p < 0.001).

Conclusions

Neutrophil–lymphocyte ratio may be a useful marker of inflammation in patients with AS. Monocyte–lymphocyte ratio and PLR require further investigation. Peripheral blood tests are simple and inexpensive to perform, making hematological markers promising tools for monitoring inflammatory diseases.

Schlagwörter

Stichwörter der Autor:innen

adalimumabankylosing spondylitisblood plateletsneutrophils

Autor:innen und Institutionen

  • Department of Rheumatology and Systemic Connective Tissue Diseases, Medical University of Lublin, Poland.

ORCID-Profile: Dominika Szlichta, Magdalena Dryglewska, Ewa Łyś-Toporowska, Maria Majdan

Zitieren

APA

Szlichta, D., Dryglewska, M., Łyś-Toporowska, E., & Majdan, M. (2026). Changes in hematological indices during adalimumab therapy in ankylosing spondylitis: a one-year retrospective study. Rheumatology, 64(3), 174-180. https://doi.org/10.5114/reum/214444

Vancouver

Szlichta D, Dryglewska M, Łyś-Toporowska E, Majdan M. Changes in hematological indices during adalimumab therapy in ankylosing spondylitis: a one-year retrospective study. Rheumatology. 2026;64(3):174-180. doi:10.5114/reum/214444

BibTeX
@article{Szlichta2026,
  author = {Szlichta, Dominika and Dryglewska, Magdalena and Łyś-Toporowska, Ewa and Majdan, Maria},
  title = {Changes in hematological indices during adalimumab therapy in ankylosing spondylitis: a one-year retrospective study},
  journal = {Rheumatology},
  year = {2026},
  volume = {64},
  number = {3},
  pages = {174--180},
  doi = {10.5114/reum/214444}
}
Kostenlos starten →